AURORA, Canada — The Ontario government has announced a significant financial injection into the life sciences sector, awarding Piramal Pharma Solutions (PPS) a grant of over $1.75 million to bolster drug substance manufacturing at its facility in Aurora, Ontario. The investment, delivered through the province’s Life Sciences Scale-Up Fund (LSSUF), is part of a broader $5.3 million capital project aimed at modernizing site infrastructure and enhancing domestic pharmaceutical production.
The strategic funding is designed to accelerate the commercialization of Ontario-made health technologies for international markets. By upgrading the facility’s R&D capabilities and scaling up clinical Active Pharmaceutical Ingredient (API) production, the project aims to stabilize the supply chain for critical drug substances while fostering a more resilient life sciences ecosystem within the province.
The initiative serves as a major win for the local labor market. According to company officials, the investment will result in the creation of 12 new high-skilled jobs while securing 183 existing positions at the Aurora site.
“We are grateful to the Government of Ontario and MPP Dawn Gallagher Murphy for their support of this important investment in our Aurora facility,” said Peter DeYoung, CEO of Piramal Global Pharma. “This funding will help enable Piramal Pharma Solutions to upgrade our site infrastructure, strengthen our manufacturing capabilities, and enhance our ability to serve patients and customers around the world.”
Beyond production capacity, the upgrades are expected to drive improvements in operational efficiency and site sustainability. DeYoung noted that the investment aligns with the company’s long-term environmental goals, stating, “In addition to supporting business growth, this investment will help advance projects focused on sustainability and the modernization of our site, reinforcing our commitment to responsible manufacturing and environmental stewardship.”
This latest development marks a period of rapid global expansion for Piramal Pharma Solutions. The company has been aggressively scaling its infrastructure across continents, including the recent launch of a new spray drying suite at its peptide facility in Turbhe, India, this past August. Furthermore, the company is diversifying its energy profile abroad, recently announcing plans to construct a 4.3 MWp ground-mounted solar power plant at its integrated facility in Morpeth, United Kingdom.
For Ontario, the partnership with PPS highlights a commitment to positioning the province as a global leader in the pharmaceutical sector. By prioritizing advanced manufacturing and domestic API development, the government intends to ensure that Ontario-based companies remain competitive in a rapidly evolving global health landscape, ultimately delivering next-generation medical treatments to patients on a worldwide scale.
As the Aurora facility undergoes these technological upgrades, the investment stands as a cornerstone of the province’s strategy to solidify its reputation as a hub for life sciences innovation, combining job creation with the critical infrastructure necessary for modern drug development.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
